Portfolio - o2h ventures

o2h ventures has so far invested in 25 promising early stage biotech companies in the UK from the Human Health EIS fund as well as angel investments.

CardiaTec Biosciences

Applying artificial intelligence on large-scale multiomic data to develop the next generation of cardiovascular disease drug targets

Alevin Therapeutics

Developing a platform of novel small molecule RGD integrin inhibitors with superior drug-like qualities.

Neurocentrx Pharma Ltd

Developing medicines to treat patients with neurological conditions.

Xploro

Using artificial intelligence, augmented reality and games to reduce stress and anxiety and improve patient outcomes

Neucruit

Intelligent lead generation for clinical trial recruitment

BiVictriX

Leveraging frontline clinical experience for the development of next generation cancer therapies

Sanome

Building a human health passport by combining multiple biomarkers

Monument Therapeutics

Bringing Precision Medicine to Neuroscience Drug Development

Stingray Bio

By targeting neglected but essential cancer kinases, the Company aims to generate next-generation oncology therapeutics for cancer patients.

Kuano

De-risking and accelerating drug discovery by combining quantum and AI

Spirea

Linking targeted cancer therapy to better patient outcomes

Tay Therapeutics

Because skin matters

Cortirio

Portable diagnosis of brain injuries

Stemnovate

Drug Toxicity Testing

Arecor

Developing ultra rapid and ultra concentrated insulin

NeoPhore

Discovering novel medicines that uses the bodies immune system to fight cancer

Opal Oncology

New therapeutics to treat brain cancer

Sentinel Oncology

New medicines to treat cancer indications and rare diseases

Talisman Therapeutics

Human stem cell drug discovery services

Five Alarm Bio

Seeking to develop drugs to slow down the ageing process

Oppilotech

New antibiotics to overcome drug resistance based on proprietary machine learning platform

PhoreMost

New drug target identiﬁcation platform

Privitar

Data Privacy. Secondary, Series, Led by Warburg Pincus (~20X)

Acacia Pharma

Novel medicine to support cancer therapy IPO MAR 2018 (EURONEXT: ACPH.BR (~9X))

PharmEnable

Diverse database of synthesiable compounds used to ﬁnd start points for new research programmes

Qkine

Re-defining growth factor and cytokine quality to advance stem cell, organoid and regenerative medicine

Heartfelt Technologies

Automatic, Non-Contact Home Heart Failure Monitoring For The Casually Compliant Patient

Neurofenix

Developing medical devices for the upper limb rehabilitation of stroke patients

Turbine

Turbine models how cancer works on the molecular level and tests millions of potential drugs on it with artiﬁcial intelligence

Pencil Biosciences

Next generation gene editing technology

AI VIVO

Intelligent Systems Pharmacology powered by Artiﬁcial Intelligence. Breakthrough information against COVID-19

Small Pharma Limited

Use known actives in certain recreational drugs to treat mental health conditions

SomaServe

The 'bionic nanoparticle' company using Polynaut for Pharma services and live cell imaging

Metrion Biosciences

Electrophysiology screening services to support client medicinal chemistry optimisation programmes

DeepMatter

Digitizing pharmaceutical chemistry (AIM: DMTR.L)

Oxford Drug Design

Machine learning platfrom used to ﬁnd ligands for Aminoacyl tRNA Synthetases

Exonate

Novel medicine as a drop to target disease of the eye

our full portfolio

Order

Status

Therapautics Area

Investment Type

1 – You could lose all the money you invest

our full portfolio

Order

Status

Therapautics Area

Investment Type

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

2 – You are unlikely to be protected if something goes wrong

3 – You won’t get your money back quickly

4 – Don’t put all your eggs in one basket

5 – The value of your investment can be reduced